Baseline sampling [Regulatives / Guidelines]

posted by NK – India, 2019-06-26 07:25 (758 d 11:17 ago) – Posting: # 20360
Views: 2,388

Hello everyone,

I have a question with regards to FDA OGD guidance of Dihydroergotamine Nasal Spray" dated February 2019.

The guidance specified that "baseline corrected PK data of AUC and Cmax should be used for bio-equivalence calculation"

As per my understanding, Dihydroergotamine is neither endogenous nor available in the diet, then why baseline value is required?

If it is required, what should be baseline sampling time points (-1h or -30 min or -15 min ...)?

Thanks in advance.

Regards
NK


Edit: URL corrected. [Helmut]

Complete thread:

Activity
 Admin contact
21,589 posts in 4,512 threads, 1,530 registered users;
online 8 (1 registered, 7 guests [including 5 identified bots]).
Forum time: Friday 18:43 CEST (Europe/Vienna)

Statistics is the grammar of science.    Karl Pearson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5